Efficacy and tolerance of an emollient on babies and children with atopic dermatitis

Atopic dermatitis is one of the most prevalent inflammatory skin diseases, preferentially affecting children, progressing by flare ups. It results in itchy, red, swollen, and cracked skin. The disease has no cure, but emollients, corticosteroids and antihistamines help lessen the symptoms and effects of the disease. One of the most documented consequences of AD on babies and children is a decrease in quality of sleep, this could lead, in the growing child, to difficulties in managing emotions and behavioral problems. An emollient with active ingredients including shea butter, niacinamide, thermal spring water, APF (a biomass of Vitreoscilla Filiformis grown in TSW) and microresyl has been developed to restore skin barrier, rebalance microbiome, and prevent the excessive proliferation of staphylococci by fighting against the persistence of bacteria and the creation of biofilm. To evaluate the efficacy and tolerance of this emollient in babies and children, we carried an observational study from pediatricians’ private consultations data.